CPA - Conference


Date: Sep 24, 2024 06:00 PM - 08:30 PM

Fee

$0.00

CE Hours

2.50

CE Units

0.250

Registration closes on Nov 08, 2024 10:00 PM

Activity Type

Knowledge

Target Audience(s)

Pharmacist

Accreditation(s)

Accreditation Council for Pharmacy Education
Accreditation Statement: Howard University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

 

Registration closes on Nov 08, 2024 at 10:00 PM

Registration Closed  

Objectives

  • Identify the recommended populations for PrEP usage as outlined by current healthcare guidelines within the context of HIV prevention.
  • List at least three barriers to PrEP adherence
  • Explain four strategies to enhance PrEP adherence among users

Speaker(s)/Author(s)

Derrick Darbouze, PharmD.

Activity Number

0010-9999-24-059-L02-P
Date: 09/24/24
Time: 06:00 PM - 06:45 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

Objectives

  • Describe the mechanism of action, indications for use, and efficacy and safety of injectable antiretrovirals, e.g., cabotegravir, rilpivirine, lenacapavir and ibalizumab.
  • Outline updated data for long acting injectable (LAI) cabotegravir/rilpivirine for treatment.
  • Explain monitoring strategies for oral vs. injectable HIV pre-exposure prophylaxis (PrEP).

Speaker(s)/Author(s)

John Hogan, MD

Activity Number

0010-9999-24-060-L02-P
Date: 09/24/24
Time: 06:45 PM - 07:30 PM

CE Hours

0.75
Registration Closed  

Registration Closed  

Objectives

  • Explain pharmacovigilance and its relationship with medication safety in the care of populations including persons living with HIV infection.
  • Identify 3 external and internal sources of pharmacovigilance data available to practicing pharmacy professionals for long acting injectable antiretrovirals (ARVs).
  • Describe the FDA Adverse Event Reporting System (FAERS II) and how pharmacy professionals and other health professionals support and use it to advance safe use on long acting injectable ARVs, e.g., cabotegravir and rilpivirine.

Speaker(s)/Author(s)

Dr. Christopher Keeys, Pharm.D.,BCPS, Pharm.D., BCPS
President, Clinical Pharmacy Associates, Inc.

Activity Number

0010-9999-24-061-L05-P
Date: 09/24/24
Time: 07:30 PM - 08:30 PM

CE Hours

1.00
Registration Closed